A Brief Review on the Novel Therapies for Painful Diabetic Neuropathy
ReviewHumans
- Design
- Review
- Subjects
- Not stated in the abstract
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- What's new in treating painful diabetic neuropathy: a brief review of current drugs, capsaicin and spinal cord stimulation, plus newer targets including palmitoylethanolamide and the endocannabinoid system.
What the authors reported
First-line drugs, capsaicin and spinal cord stimulation are covered alongside newer targets such as NMDA receptors and the endocannabinoid system. The authors say treatments such as palmitoylethanolamide and other endocannabinoid targets have extremely limited clinical trials, that many studies did not measure function, and that measurement methods were inconsistent.
Limits of this study
A brief narrative review; no trial numbers or PEA data are given. Funding and conflicts not stated in the abstract.
Source
PubMed 37392335 · doi:10.1007/s11916-023-01126-1
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.